"Pharmacoepidemiology" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
| Descriptor ID |
D017891
|
| MeSH Number(s) |
H01.158.703.045 H02.403.720.500.650 H02.628.413
|
| Concept/Terms |
Pharmacoepidemiology- Pharmacoepidemiology
- Pharmaceutical Epidemiology
- Epidemiologies, Pharmaceutical
- Pharmaceutical Epidemiologies
- Epidemiology, Pharmaceutical
|
Below are MeSH descriptors whose meaning is more general than "Pharmacoepidemiology".
Below are MeSH descriptors whose meaning is more specific than "Pharmacoepidemiology".
This graph shows the total number of publications written about "Pharmacoepidemiology" by people in this website by year, and whether "Pharmacoepidemiology" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Pharmacoepidemiology" by people in Profiles.
-
Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. Pharmacoepidemiol Drug Saf. 2022 04; 31(4):411-423.
-
A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. Am J Epidemiol. 2021 07 01; 190(7):1424-1433.
-
Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2021 06; 30(6):671-684.
-
Bias in case-crossover studies of medications due to persistent use: A simulation study. Pharmacoepidemiol Drug Saf. 2020 09; 29(9):1079-1085.
-
Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example. Value Health. 2020 02; 23(2):217-226.
-
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018 Nov 14; 363:k3532.
-
Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
-
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep; 26(9):1033-1039.
-
Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. Pharmacoepidemiol Drug Saf. 2014 Nov; 23(11):1160-7.
-
Optimal matching ratios in drug safety surveillance. Epidemiology. 2014 Sep; 25(5):772-3.